Choreito, a Kampo medicine attenuates detrusor overactivity and bladder pain symptoms in rat tranilast‐induced interstitial cystitis/bladder pain syndrome‐like model

Tokita, Yohei; Sugaya, Kimio; Nishijima, Saori; Tsuchiya, Naho; Hamaguchi, Marie; Yamamoto, Hideyuki

doi:10.1002/nau.25095

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These therapies have proven efficacies in treating urological disorders (Moran et al, 2013), but the outcomes in UCPPS patients are variable. While there are several animal studies suggesting the potential benefits of herbal therapies for IC/BPS treatment (Cui et al, 2020;Tokita et al, 2023;Wazir et al, 2021;, there were only a few well-designed clinical trials with appropriate controls and sample sizes to provide definitive conclusions about their therapeutic effects. Therefore, future translational and clinical research on the mechanisms of the herbal substances' action and their efficacy for UCPPS patients is warranted (Dashdondov et al, 2021).…”

Section: Botulinum Toxin a (Botn-a) Injections In The Urinary Bladder...mentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal model findings and clinical research advances in the field. The diagnosis of UCPPS by clinicians has room for improvement despite the changes in the past decade aiming to decrease the time to treatment. Therapeutic approaches targeting growth factors (i.e., NGF, VEGF), amniotic bladder therapy and stem cell treatments gain more attention as experimental treatment options for UCPPS. The development of novel diagnostic tests based on the latest advances in urinary biomarkers would be beneficial to assist with the clinical diagnosis of UCPPS. Future research directions should address the role of chronic psychological stress and the mechanisms of pain refractory to conventional management strategies in UCPPS etiology. Testing the applicability of cognitive behavioral therapy in this cohort of UCPPS patients might be promising to increase their QoL. The search for novel lead compounds and innovative drug delivery systems requires clinically relevant translational animal models. The role of autoimmune responses triggered by environmental factors is another promising research direction to clarify the impact of the immune system in UCPPS pathophysiology. SIGNIFICANCE STATEMENTThis minireview provides an up-to-date summary of the therapeutic approaches for UCPPS with focus on recent advancements in the clinical diagnosis and treatments of the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward.

show abstract

Section: Botulinum Toxin a (Botn-a) Injections In The Urinary Bladder...mentioning

confidence: 99%

“…Pollen extracts Eviprostat Terpene Pumpkin seed oil Anti-inflammatory Antioxidants Cui et al, 2020;Dashdondov et al, 2021;Moran et al, 2013;Pang & Ali, 2015;Tokita et al, 2023;Wazir et al, 2021…”

Section: Nonspecific Pain Urinary Symptomsmentioning

confidence: 99%

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…Thus, it is a useful and quantitative tool for assessing overall inflammation and should not be construed to indicate changes in all specific indices of inflammation. This assay is widely used as a index of inflammation in many different tissues and has been frequently used by us [17,[33][34][35]42] and others [43][44][45] in the bladder.…”

Section: Evans Blue Extravasation Assaymentioning

confidence: 99%

Specialized pro-resolution mediators in the bladder: effects of resolvin E1 on diabetic bladder dysfunction in the type 1 diabetic male Akita mouse model

Cervantes,

Hughes,

Jin

et al. 2024

BMC Urol

View full text Add to dashboard Cite

Background One of the most common, but least studied, diabetic complication is diabetic bladder dysfunction. Current therapies include glucose control and symptom-based interventions. However, efficacy of these therapies is mixed and often have undesirable side effects. Diabetes is now known to be a chronic inflammatory disease. Specialized pro-resolving mediators are a class of compounds that promote the resolution of inflammation and have been shown to be effective in treating chronic inflammatory conditions. In this study we examine the ability of resolvin E1 to improve signs of diabetic bladder dysfunction. Methods Male Akita mice (Type 1 diabetic) develop hyperglycemia at 4 weeks and signs of bladder underactivity by 15 weeks. Starting at 15 weeks, mice were given one or two weeks of daily resolvin E1 and compared to age-matched wild type and untreated Akita mice. Results Resolvin E1 did not affect diabetic blood glucose after one week, although there was a slight decrease after two weeks. Diabetes decreased body weight and increased bladder weights and this was not affected by resolvin E1. Evan’s blue dye extravasation (an indirect index of inflammation) was dramatically suppressed after one week of resolvin E1 treatment, but, surprisingly, had returned to diabetic levels after two weeks of treatment. Using cystometry, untreated Akita mice showed signs of underactivity (increased void volumes and intercontraction intervals). One week of resolvin E1treatment restored these cystometric findings back to control levels. After two weeks of treatment, cystometric changes were changed from controls but still significantly different from untreated levels, indicating a durable treatment effect even in the presence of increased inflammation at 2 weeks. Conclusions Resolvin E1 has a beneficial effect on diabetic bladder dysfunction in the type 1 diabetic male Akita mouse model.

show abstract

Strict glucose control and elimination of NLRP3‐induced inflammation prevents diabetic bladder dysfunction in the female Akita mouse model

Hughes,

Harper,

Jin

et al. 2024

Neurourology and Urodynamics

View full text Add to dashboard Cite

PurposeDiabetic bladder dysfunction (DBD) is the most common diabetic complication. Logically, regulation of blood glucose should reverse dysfunction, but the Epidemiology of Diabetes Interventions and Complications study found strict control ineffective. However, it is possible that strict control may prevent DBD if initiated before symptoms appear. We examine the effect of early glucose control on development of DBD in the female diabetic Akita mouse (Type 1) and test the potential of inhibiting/deleting NLRP3 as adjunct therapy to glucose control.Materials and MethodsFemale Akita mice were bred NLRP3+/+ or NLRP3−/−. At 6 weeks of age, diabetics received either no glucose control or insulin pellets (s.c., Linshin) designed to poorly or strictly control blood glucose. At Week 15, blood glucose (glucometer), the extravasation potential of bladder (an indirect measurement of inflammation) and bladder function (urodynamics) were assessed.ResultsBlood glucose of diabetics was reduced in poorly controlled and strongly reduced in strictly controlled groups. Levels were not affected by deletion of NLRP3. Evans blue dye extravasation correlated with glucose control and was eliminated in the NLRP3−/− groups. Urodynamics found markers of overactivity in diabetics which was improved in the poorly controlled group and eliminated in the strictly controlled group. In the NLRP3−/− mice, no bladder dysfunction developed, regardless of glucose control.ConclusionsEarly‐initiated strict glycemic control and NLRP3 elimination can effectively prevent DBD, suggesting hyperglycemia acts through NLRP3‐induced inflammation to trigger DBD.

show abstract

Choreito, a Kampo medicine attenuates detrusor overactivity and bladder pain symptoms in rat tranilast‐induced interstitial cystitis/bladder pain syndrome‐like model

Cited by 5 publications

References 23 publications

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Specialized pro-resolution mediators in the bladder: effects of resolvin E1 on diabetic bladder dysfunction in the type 1 diabetic male Akita mouse model

Strict glucose control and elimination of NLRP3‐induced inflammation prevents diabetic bladder dysfunction in the female Akita mouse model

Contact Info

Product

Resources

About